Pulmatrix Inc

NASDAQ PULM

Data sourced from iex and EODHD
Download Data

Pulmatrix Inc Interest Expense To Sales 1 year YoY Change (%) for the quarter ending December 31, 2023: 452.06%

Pulmatrix Inc Interest Expense To Sales 1 year YoY Change (%) is 452.06% for the quarter ending December 31, 2023, a 552.06% change year over year. The interest expense to sales ratio is a financial metric that represents the proportion of a company's revenue that is used to cover its interest expenses. It is calculated by dividing the company's interest expense by its total revenue. This ratio indicates the financial burden of interest payments on the company's operating income. A higher ratio suggests that a significant portion of the company's revenue is being used to service interest obligations, potentially affecting its profitability. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Pulmatrix Inc Interest Expense To Sales for the quarter ending March 31, 2023 was -9.14%, a -10,701.73% change year over year.
  • Pulmatrix Inc Interest Expense To Sales for the quarter ending March 31, 2022 was 0.09%.
NASDAQ: PULM

Pulmatrix Inc

CEO Mr. Teofilo David Raad MBA
IPO Date March 21, 2014
Location United States
Headquarters 99 Hayden Avenue, Lexington, MA, United States, 02421
Employees 22
Sector Healthcare
Industry Biotechnology
Description

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

StockViz Staff

September 20, 2024

Any question? Send us an email